Market and Technology Analysis

Eye on Cord Blood for Cell Therapy

A snapshot of this evolving market landscape.

The changing profile of hematopoietic stem cell transplantation is among the topics discussed in this report, available for download below.

(Page
1
of
1)

The focus of this GEN Market & Tech Analysis report is to characterize the cord blood marketplace as it relates to cellular therapy based on the following classes of data, which we have been collecting as part of the industry analysis of this field:

Growth of cord blood units in the public banks

Quantitative utilization trends of cord blood

Evolution of this space

Current status of cord blood banking

Taken together, these data frame the current quantitative metrics and provide a snapshot of the cord blood space.

Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at enal@selectbio.us.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.